The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region
- PMID: 15681799
- DOI: 10.1196/annals.1332.003
The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region
Abstract
The Alzheimer's amyloid precursor protein (APP) is the metalloprotein that is cleaved to generate the pathogenic Abeta peptide. We showed that iron closely regulated the expression of APP by 5'-untranslated region (5'-UTR) sequences in APP mRNA. Iron modulated APP holoprotein expression by a pathway similar to iron control of the translation of the ferritin-L and -H mRNAs by iron-responsive elements in their 5'-UTRs. APP gene transcription is also responsive to copper deficit where the Menkes protein depleted fibroblasts of copper to suppress transcription of APP through metal regulatory and copper regulatory sequences upstream of the APP 5' cap site. APP is a copper-zinc metalloprotein and chelation of Fe(3+) by desferrioxamine and Cu(2+) by clioquinol appeared to provide effective therapy for the treatment of AD in limited patient studies. We have introduced an RNA-based screen for small APP 5'-UTR binding molecules to identify leads that limit APP translation (but not APLP-1 and APLP-2) and amyloid Abeta peptide production. A library of 1200 drugs was screened to identify lead drugs that limited APP 5'-UTR-directed translation of a reporter gene. The efficacy of these leads was confirmed for specificity in a cell-based secondary assay to measure the steady-state levels of APP holoprotein relative to APLP-1/APLP-2 by Western blotting. Several chelators were identified among the APP 5'-UTR directed leads consistent with the presence of an IRE stem-loop in front of the start codon of the APP transcript. The APP 5'-UTR-directed drugs--desferrioxamine (Fe(3+) chelator), tetrathiomolybdate (Cu(2+) chelator), and dimercaptopropanol (Pb(2+) and Hg(2+) chelator)--each suppressed APP holoprotein expression (and lowered Abeta peptide secretion). The novel anticholinesterase phenserine also provided "proof of concept" for our strategy to target the APP 5'-UTR sequence to identify "anti-amyloid" drugs. We further defined the interaction between iron chelation and phenserine action to control APP 5'-UTR-directed translation in neuroblastoma (SY5Y) transfectants. Phenserine was most efficient to block translation under conditions of intracellular iron chelation with desferrioxamine suggesting that this anticholinesterase operated through an iron (metal)-dependent pathway at the APP 5'-UTR site.
Similar articles
-
Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.J Neurochem. 2006 Apr;97(2):527-36. doi: 10.1111/j.1471-4159.2006.03770.x. Epub 2006 Mar 15. J Neurochem. 2006. PMID: 16539659
-
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript.J Biol Chem. 2002 Nov 22;277(47):45518-28. doi: 10.1074/jbc.M207435200. Epub 2002 Aug 26. J Biol Chem. 2002. PMID: 12198135
-
Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator.J Neural Transm Suppl. 2006;(71):237-47. doi: 10.1007/978-3-211-33328-0_25. J Neural Transm Suppl. 2006. PMID: 17447434
-
Targeting the Iron-Response Elements of the mRNAs for the Alzheimer's Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity.Int J Mol Sci. 2019 Feb 25;20(4):994. doi: 10.3390/ijms20040994. Int J Mol Sci. 2019. PMID: 30823541 Free PMC article. Review.
-
Iron-Mediated Overexpression of Amyloid Precursor Protein via Iron Responsive mRNA in Alzheimer's Disease.Int J Mol Sci. 2025 May 30;26(11):5283. doi: 10.3390/ijms26115283. Int J Mol Sci. 2025. PMID: 40508094 Free PMC article. Review.
Cited by
-
The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.J Neural Transm (Vienna). 2011 Mar;118(3):493-507. doi: 10.1007/s00702-010-0513-5. Epub 2011 Jan 8. J Neural Transm (Vienna). 2011. PMID: 21221670 Free PMC article.
-
Recent Advances in Targeting Transition Metals (Copper, Iron, and Zinc) in Alzheimer's Disease.Mol Neurobiol. 2024 Dec;61(12):10916-10940. doi: 10.1007/s12035-024-04256-8. Epub 2024 May 29. Mol Neurobiol. 2024. PMID: 38809370 Review.
-
Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.Neurochem Res. 2005 Jun-Jul;30(6-7):895-908. doi: 10.1007/s11064-005-6962-9. Neurochem Res. 2005. PMID: 16187224 Review.
-
Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis.Biochem Pharmacol. 2014 Apr 15;88(4):486-94. doi: 10.1016/j.bcp.2014.01.032. Epub 2014 Feb 7. Biochem Pharmacol. 2014. PMID: 24513321 Free PMC article. Review.
-
Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.J Nanoneurosci. 2009 Jun 1;1(1):42-55. doi: 10.1166/jns.2009.005. J Nanoneurosci. 2009. PMID: 19936278 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous